The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis.
暂无分享,去创建一个
Ivana V. Yang | Adrianne L. Stefanski | D. Lynch | D. Schwartz | K. Brown | S. Groshong | J. Thurman | V. M. Holers | G. Cosgrove | M. Schwarz | I. Yang | C. Hennessy | A. Walts | C. Cool | N. Banda | S. Mathai | Corinne E. Hennessy | T. Okamoto | Laura A Hancock | V. Holers | D. A. Schwartz | Laura A. Hancock | Nirmal K. Banda | Susan K. Mathai | Corinne E. Hennessy | Laura A. Hancock | Avram D. Walts | Adrianne L. Stefanski | David A. Lynch | Gregory P. Cosgrove | Steve D. Groshong | Carlyne D. Cool | Marvin I. Schwarz | Joshua M. Thurman | Marvin I. Schwarz | David A. Schwartz | Tsukasa Okamoto | Kevin K. Brown | David A. Lynch | Ivana V. Yang
[1] R. Sussman,et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.
[2] O. Cummings,et al. Crosstalk between TGF‐β1 and complement activation augments epithelial injury in pulmonary fibrosis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] John D Lambris,et al. Generation of C5a in the absence of C3: a new complement activation pathway , 2006, Nature Medicine.
[4] T. Mitchell,et al. Innate Immune Defense against Pneumococcal Pneumonia Requires Pulmonary Complement Component C3 , 2005, Infection and Immunity.
[5] H. Collard,et al. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. , 2014, Respiratory medicine.
[6] B. Moore,et al. Latent herpesvirus infection augments experimental pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.
[7] M. Merrow,et al. Biosynthesis of the third and fifth complement components by isolated human lung cells. , 1989, The American review of respiratory disease.
[8] R. Strunk,et al. Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. , 1988, The Journal of clinical investigation.
[9] R. Sanyi,et al. The Overlapping Roles of Antimicrobial Peptides and Complement in Recruitment and Activation of Tumor-Associated Inflammatory Cells , 2015, Front. Immunol..
[10] Takeshi Johkoh,et al. American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .
[11] D. Vergani,et al. Complement activation products in idiopathic pulmonary fibrosis: relevance of fragment Ba to disease severity. , 1990, Clinical immunology and immunopathology.
[12] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.
[13] Elissa Murphy,et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. , 2014, American journal of respiratory and critical care medicine.
[14] Ivana V. Yang,et al. Muc5b is required for airway defence , 2013, Nature.
[15] J. Köhl,et al. A complex role for complement in allergic asthma , 2010, Expert review of clinical immunology.
[16] Brent S. Pedersen,et al. Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis. , 2016, American journal of respiratory and critical care medicine.
[17] Ivana V. Yang,et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. , 2011, The New England journal of medicine.
[18] E. Mickler,et al. Role of Complement Activation in Obliterative Bronchiolitis Post–Lung Transplantation , 2013, The Journal of Immunology.
[19] Ivana V. Yang,et al. Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. , 2016, Physiological reviews.
[20] A. Theofilopoulos,et al. Circulating immune complexes in the idiopathic interstitial pneumonias. , 1978, The New England journal of medicine.
[21] A. Schutte,et al. Local immune complexes and inflammatory response in patients with chronic interstitial pulmonary disorders associated with collagen vascular diseases. , 1984, Clinical and experimental immunology.
[22] J. Köhl,et al. On the role of complement and Fc γ-receptors in the Arthus reaction , 1999 .
[23] R. Strieter. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. , 2005, Chest.
[24] W. J. Matthews,et al. Complement biosynthesis by human bronchoalveolar macrophages. , 1983, Clinical immunology and immunopathology.
[25] Ivana V. Yang,et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis , 2013, Thorax.
[26] P. Korošec,et al. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. , 2004, American journal of respiratory cell and molecular biology.
[27] R. Thrall,et al. Inhibition of bleomycin-induced pulmonary fibrosis by cobra venom factor. , 1982, The American journal of pathology.
[28] Brent S. Pedersen,et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis , 2013, Nature Genetics.
[29] O. Cummings,et al. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] Bärbel Rohrer,et al. Detection of complement activation using monoclonal antibodies against C3d. , 2013, The Journal of clinical investigation.
[31] F. Sciurba,et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. , 2013, American journal of respiratory and critical care medicine.
[32] H. Collard,et al. Epidemiology of idiopathic pulmonary fibrosis , 2013, Clinical epidemiology.
[33] J. Köhl,et al. Opposing Regulatory Roles of Complement Factor 5 in the Development of Bleomycin-Induced Pulmonary Fibrosis1 , 2005, The Journal of Immunology.
[34] N. Sheerin,et al. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. , 2009, Journal of the American Society of Nephrology : JASN.
[35] D. Wilkes,et al. Complement system in lung disease. , 2014, American journal of respiratory cell and molecular biology.
[36] L. Abdullah,et al. Munc13‐2−/− baseline secretion defect reveals source of oligomeric mucins in mouse airways , 2008, The Journal of physiology.
[37] M. Pangburn,et al. The Critical Role of Complement Alternative Pathway Regulator Factor H in Allergen-Induced Airway Hyperresponsiveness and Inflammation , 2012, The Journal of Immunology.